0
0
In a significant breakthrough, Mayo Clinic researchers have identified what may be the earliest biological warning signs of ovarian cancer, a disease notoriously difficult to detect in its initial stages. This discovery, published in JCO Precision Oncology, could pave the way for new strategies in early detection and prevention, especially for women with inherited genetic risks.
The research was sparked by the case of a 22-year-old woman carrying two rare genetic mutations: BRCA2, linked to hereditary breast and ovarian cancer (HBOC) syndrome, and TP53, the cause of Li-Fraumeni syndrome. Both mutations dramatically increase a person’s lifetime risk of developing cancer. The patient, already diagnosed with breast cancer, was found to have a benign ovarian cyst during her evaluation at Mayo Clinic. Given her high risk, she elected to undergo a bilateral mastectomy, hysterectomy, and removal of her ovaries and fallopian tubes.
Upon examining her fallopian tube tissue after surgery, Mayo Clinic scientists discovered subtle cellular abnormalities—changes that may represent the very first warning signs of ovarian cancer, appearing well before any symptoms or visible tumors develop. Using advanced single-cell RNA sequencing, the team found that the normal balance of epithelial cells in her fallopian tubes was disrupted: secretory cells vastly outnumbered multiciliated cells, and chronic inflammation was present—both factors known to contribute to cancer development.
Dr. Nagarajan Kannan, director of the Stem Cell and Cancer Biology Laboratory at Mayo Clinic and co-lead author, emphasized the significance of these findings:
“These insights could pave the way for future strategies to detect the disease in its earliest, precancerous stages when prevention is still possible,” Dr. Kannan said.
To further advance research, Mayo Clinic has established a living fallopian tube biobank, allowing scientists to grow organoids—miniature models of the fallopian tubes—from patient-donated cells. This resource will help researchers investigate how ovarian cancer begins and identify potential targets for early intervention, particularly in those with inherited mutations like BRCA2 and TP53.
Dr. Jamie Bakkum-Gamez, the patient’s gynecologic oncology surgeon and co-lead author, noted:
“Knowing how ovarian cancer begins and forms could not only lead to the development of earlier screening tools, but also more personalized risk-reduction strategies and improved guidance around the timing of preventive surgeries and fertility planning,” she said.
Currently, ovarian cancer is often diagnosed only after it has reached advanced stages, with about 75% of cases identified at stage 3 or 4. The Mayo Clinic’s findings offer hope for a future where the disease can be caught much earlier, improving outcomes and saving lives.
Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you have concerns about your health or risk factors for ovarian cancer, please consult a qualified healthcare provider.
